Since this drug was developed on public funding in the UK, how does that affect its pricing and incorporation in the NHS? I assume whoever gets the license to sell it in the US will have exclusivity and make it expensive as hell.

edit: Never mind, although the research took place at the University of London, it was funded by Ionis Pharmaceuticals (US) and further by Roche (Swiss multinational). The Guardian article relegates that bit of info to the very last line, as if they were just a minor part of the effort. http://markets.businessinsider.com/news/stocks/Ionis-Pharmac...